Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancerReport as inadecuate

Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer - Download this document for free, or read online. Document in PDF available to download.

BMC Cancer

, 6:16

First Online: 23 January 2006Received: 07 July 2005Accepted: 23 January 2006DOI: 10.1186-1471-2407-6-16

Cite this article as: Jiang, W.G., Watkins, G., Douglas-Jones, A. et al. BMC Cancer 2006 6: 16. doi:10.1186-1471-2407-6-16


BackgoundAngiomotin is a newly discovered molecule that regulates the migration and tubule formation of endothelial cells. It therefore has been implicated in the control of angiogenesis under physiological and pathological conditions. This study examined the expression of angiomotin and its analogues, angiomotin-like 1 L1 and -like 2 L2 in breast tumour tissues, and analysed their correlation with angiogenesis and clinical outcomes.

MethodsHuman breast tissues normal n = 32 and tumours n = 120 were used. The levels of expression of angiomotin, L1 and L2 were determined using reverse transcription PCR. Microvessels were stained using antibodies against PECAM, von Willebrand factor factor 8, or vWF and VE-cadherin. The transcript levels of angiomotin and its analogues were assessed against the clinical and pathological background, including long term survival 120 months.

ResultsBreast cancer tissues expressed significantly higher levels of angiomotin transcript, compared with normal mammary tissues 33.1 ± 11 in normal versus 86.5 ± 13.7 in tumour tissues, p = 0.003. Both L1 and L2 were seen at marginally higher levels in tumour than normal tissues but the difference was not statistically significant. Levels of angiomotin were at significantly higher levels in grade 2 and grade 3 tumours compared with grade 1 p < 0.01 and p = 0.05 respectively. The levels of angiomotin in tumours from patients who had metastatic disease were also significantly higher than those patients who remained disease free p = 0.03. Multivariate analysis indicated that angiomotin transcript was an independent prognostic factor p = 0.031. No significant correlations were seen between angiomotin-L1 and L2 with the clinical outcome. Furthermore, high levels of angiomotin transcript were associated with shorter overall survival p < 0.05. There was a high degree of correlation between levels of vW factor and that of angiomotin p < 0.05, but not angiomotin-L1 and angiomotin-L2.

ConclusionAngiomotin, a putative endothelial motility factor, is highly expressed in human breast tumour tissues and linked to angiogenesis. It links to the aggressive nature of breast tumours and the long term survival of the patients. These data point angiomotin as being a potential therapeutic target.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2407-6-16 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Author: Wen G Jiang - Gareth Watkins - Anthony Douglas-Jones - Lars Holmgren - Robert E Mansel


Related documents